CognitMarket market news, portfolio research, and investor insights

Your market command center

Research the market. Understand your portfolio. Act with confidence.

Turn market-moving news into a focused daily view of the companies, portfolios, and ideas you care about.

Login
Create my free account
Free to start · No card required

Top Stories

The developments most likely to shape today’s market conversation.
Parabilis reports 72% response rate for desmoid tumor drug
Company News

Parabilis reports 72% response rate for desmoid tumor drug

INVESTING.COM

Parabilis Medicines (Nasdaq: PBLS) presented updated Phase 1/2 clinical data for its investigational drug zolucatetide in desmoid tumor patients at the European Society for Medical Oncology Congress on Oct. 24, 2026, in Madrid, Spain.

Among response-evaluable patients who began treatment at a starting dose of 450 mg or higher, the drug showed an objective response rate of 72.2% (13 of 18 patients) in a 32-week landmark analysis, based on a June 22, 2026, data cutoff. A disease control rate of 100% was observed across all 46 response-evaluable patients receiving that starting dose, with no disease progression recorded.

As of the data cutoff, 76 patients had been enrolled and treated across all dose levels. Median age was 37 years, and 69.7% of patients were female. Treatment-related adverse events were predominantly low-grade, with fatigue, alopecia, and nausea most commonly reported. No patients discontinued treatment due to treatment-related adverse events.

Data from a three-arm ra

Biotech stocks are surging. How investors can play the new drug innovation boom
Sector News

Biotech stocks are surging. How investors can play the new drug innovation boom

CNBC.COM

In this article

Moderna gave investors a scare as its stock plunged on Thursday. But it’s still one of the hottest biotechs this year. And it’s hardly alone – the sector is on a roll and looks poised for more gains.

The iShares Biotechnology ETF (IBB) is up 24% through October 23, building on a 28% gain in 2025. Two dozen of the ETF’s 233 holdings have more than doubled year-to-date. Moderna leads the pack with a 587% surge — even after an 18% decline following a leak of clinical data for its cancer vaccine (which was actually positive).

Analysts say a new biotech cycle is underway, fueled by clinical trial results, M&A activity, and promising technologies such as genomics, mRNA — and AI.

“We’re in the midst of a powerful innovation cycle,” said John Hall, portfolio manager of the T. Rowe Price Biotechnology ETF. “What’s super exciting is we’re seeing newer modalities start to make it to market.” Companies “understand the disease biology better,” he adds, and that could ultimately

2 ex-FBI officials charged with lying about involvement in investigation into Hunter Biden’s laptop
Company News

2 ex-FBI officials charged with lying about involvement in investigation into Hunter Biden’s laptop

APNEWS.COM

WASHINGTON (AP) — Two former FBI officials were charged Friday with lying to Congress about their involvement in investigating Hunter Biden’s laptop in the run-up to the 2020 presidential election, the latest in a series of splashy and politically charged actions the Justice Department has undertaken ahead of next month’s midterm contests.

Nikki Floris and Bradley Benavides, former leaders of a since-disbanded task force set up to counter foreign election interference, appeared in federal court in Washington, where their lawyers pressed for a speedy hearing to contest allegations their clients lied to lawmakers by saying that they did not participate in FBI investigations of Biden.

The prosecution, a rare Department of Justice criminal case against a former employee, revisits a tangled and peculiar saga that roiled the final weeks of the 2020 race. It also comes amid a broader, backward-looking effort by FBI Director Kash Patel, who before taking over the nation’s premier law enforce

Compass Therapeutics publishes tovecimig trial results in JCO
Company News

Compass Therapeutics publishes tovecimig trial results in JCO

INVESTING.COM

BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX) announced the publication of results from its Phase 2/3 COMPANION-002 study evaluating tovecimig combined with paclitaxel in patients with previously treated advanced biliary tract cancer in the Journal of Clinical Oncology.

The randomized study enrolled 168 patients with advanced biliary tract cancer who had received one prior therapy, assigning them 2:1 to receive tovecimig plus paclitaxel or paclitaxel alone. The trial met its primary endpoint, showing an objective response rate of 18.0% versus 5.3% with paclitaxel alone, according to the press release statement.

The study also met its key secondary endpoint of progression-free survival, with a median of 4.7 months versus 2.6 months for paclitaxel alone, representing a 56% reduction in the risk of disease progression or death. The median duration of response was 4.9 months, and the disease control rate was 62.2% versus 36.8%.

In patients with intrahepatic cholangiocarcinoma, a pre

France’s luxury stores board up windows ahead of fresh protests
Sector News

France’s luxury stores board up windows ahead of fresh protests

CNBC.COM

In this article

Luxury boutiques in France boarded up their normally glitzy windows and added guards ahead of fresh protests on Saturday, with some planning to stay closed after rioters looted shops across the country last weekend.

France draws large numbers of overseas shoppers seeking Chanel handbags and Hermes scarves, an important source of revenue for brands facing slowing demand.

But some decided staying open was too risky after last week’s events, when rioters smashed and looted hundreds of shops in Paris, Marseille and Bordeaux.

A Rolex retailer and a De Beers store near the capital’s famous Place Vendome will remain closed on Saturday, staff said, while managers at stores including Richemont-owned IWC said they would decide whether to close early depending on the intensity of the protests.

Groups including France’s main student union UNEF and the Yellow Vest group, which emerged as a potent anti-establishment movement in 2018, plan to march through central Paris later on

The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.
Market Summary

The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.

FOOL.COM

The Nasdaq Composite (^IXIC -0.21%) fell 2.6% on Oct. 22, closing at 26,008.86 and marking the largest decline since a 4.2% drop on June 5.

Here's the level that would put the Nasdaq in a correction, why corrections are occurring more frequently, and how you can prepare for volatility.

A correction is defined as a drop of at least 10% from the highs, and a bear market is a prolonged period of decline of at least 20% from the highs.

Based on the Oct. 22 close, the Nasdaq would need to drop an additional 4.1% to reach a correction. If that happens, it will mark the third correction this year. Although the last two corrections were brief.

Historically, stock market corrections have occurred every one to two years. Lately, they have been happening with increasing speed and frequency. However, the recoveries have also been swift.

As you can see in the chart, most declines of more than 10% in the Nasdaq over the last decade were fully recovered within a matter of months. In fact, the on

1 / 6

For You

Personalize this briefing around the investments you care about.

Follow the market through your own lens.

Create a free account to bring watchlist updates, portfolios, and Autopilot status into this briefing.

Trending now

Top portfolios

From the Community

Recent questions, research, and investing ideas from members.

The Biotech sector is experiencing a significant innovation boom, with the iShares Biotechnology ETF (IBB) up 24% year-to-date through October 23, building on a 28% gain in 2025 . Analysts point to a powerful innovation cycle driven by clinical trial results, M&A activity, and promising technologies like genomics, mRNA, and AI .

Key drivers:

  • Innovation Cycle: New modalities and improved disease biology understanding are leading to novel drug development.
  • FDA Approvals: 12 novel biologic drugs approved in 2025, with 66 novel drugs in the pipeline.
  • AI Integration: AI and machine learning are accelerating drug discovery and development, creating predictive models previously unattainable .

This broad sector strength suggests continued investor interest in biotech innovation.

Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are surging. How investors can play the new drug innovation boom

CNBC.COMOct 24, 6:56 PM UTC
1

Allegiant Travel (ALGT) has exercised options to acquire six additional Boeing 737-8 aircraft from Boeing (BA). The jets, with a list price exceeding $720 million, are slated for delivery in 2028 . This expands Allegiant's firm order book with Boeing to 56 aircraft, signaling continued fleet modernization and growth plans .

Allegiant Travel exercises Boeing aircraft options and signs new executive contracts

Allegiant Travel exercises Boeing aircraft options and signs new executive contracts

INVESTING.COMOct 23, 10:46 PM UTC
Allegiant exercises options for six Boeing 737 MAX jets worth over $720 million

Allegiant exercises options for six Boeing 737 MAX jets worth over $720 million

INVESTING.COMOct 23, 9:48 PM UTC
1 / 2
1

Concerns over the massive debt tech companies are taking on to finance AI networks are impacting broader markets. The 10-year U.S. Treasury yield dropped below 5% this week, with investors seeking cover amid 'AI worries' . This comes as credit default swaps for some AI companies, like CoreWeave, show distressed levels . The bond market is seeing inflows, with some strategists suggesting 'The Price is Right' for adding bonds after a significant sell-off . This macro shift reflects growing investor apprehension about the financial sustainability of the AI buildout .

10-year Treasury yield drops back to 5% this week as investors seek cover from AI worries

10-year Treasury yield drops back to 5% this week as investors seek cover from AI worries

CNBC.COMOct 23, 8:20 PM UTC
Investors are starting to find opportunities in the battered bond market

Investors are starting to find opportunities in the battered bond market

CNBC.COMOct 23, 5:40 PM UTC
1 / 2
1

LKQ Corporation (NASDAQ: LKQ) shares tumbled 10% after reporting preliminary Q3 2026 results that significantly missed Wall Street expectations. The automotive parts distributor projected revenue of $3.32 billion (vs. $3.41 billion consensus) and adjusted EPS of $0.47-$0.53 (vs. $0.69 consensus), leading to an anticipated net loss of $16M-$32M .

Key points:

  • Organic revenue for parts and services fell 5.4% YoY, with European operations underperforming significantly (-9.8%).
  • CEO Justin Jude and LKQ Europe President Andy Hamilton have departed, with Salvatore A. Abbate named new CEO.
  • Full-year 2026 financial guidance has been withdrawn .

The disappointing results and leadership changes signal significant operational challenges, particularly in Europe.

LKQ stock tumbles 10% on weak Q3 results, CEO departure

LKQ stock tumbles 10% on weak Q3 results, CEO departure

STREETINSIDER.COMOct 23, 12:15 PM UTC
5

Bank of America warns of growing investor reluctance to fund AI infrastructure build-out, citing recent market signals:

  • IPO Withdrawal: AI data center developer Firmus withdrew its IPO due to weak demand .
  • Yield Spikes: CoreWeave's unsecured bond yields touched 15%, and its shares fell 15% .
  • Sector Rotation: MSCI Europe AI Capex Select index is down ~15% since early October, reversing gains. European cyclicals underperformed defensives by 11%, the worst since March 2020 .
  • Semiconductors Hit: Semiconductors are the worst performer, down 15% relative to other sectors .

BofA remains concerned about rising funding costs squeezing returns and potential monetization disappointments, echoing prior capex cycles . This comes as Nvidia's CEO visits Kazakhstan to promote AI computing hubs, highlighting ongoing global AI infrastructure expansion efforts .

BofA sees growing investor reluctance to fund AI infrastructure

BofA sees growing investor reluctance to fund AI infrastructure

STREETINSIDER.COMOct 23, 11:12 AM UTC
Nvidia’s Huang heads to Kazakhstan for the first time — and he’s not the only one with big plans

Nvidia’s Huang heads to Kazakhstan for the first time — and he’s not the only one with big plans

CNBC.COMOct 23, 9:21 AM UTC
1 / 2
5

SpaceX is in talks with Crown Castle (CCI) and other tower companies to secure 80,000 cell sites, signaling a major push to become a fourth nationwide wireless carrier.

  • Market Reaction: Crown Castle shares surged 10% on the news, while incumbent carriers AT&T (T), Verizon (VZ), and T-Mobile (TMUS) each fell around 5% .
  • Strategic Impact: This move could significantly disrupt the telecom landscape, creating a new competitor for mobile services and a substantial new revenue stream for tower operators .
  • Scale: The potential deals could be worth billions, as SpaceX aims to leverage its satellite technology with terrestrial infrastructure .
SpaceX in talks with Crown Castle to secure 80,000 US cell sites

SpaceX in talks with Crown Castle to secure 80,000 US cell sites

STREETINSIDER.COMOct 23, 8:27 AM UTC
2

New US unemployment claims fell to 194,000 last week, with the 4-week average at 197,750 – the lowest levels since 1969 . This 'low-hire, low-fire' labor market signals stability but also potential stagnation. The data reinforces the Federal Reserve's challenge in balancing its dual mandate of low inflation and low unemployment, potentially supporting continued interest rate hikes .

Unemployment Lines Are Shorter Than Any Time Since The 1960s

Unemployment Lines Are Shorter Than Any Time Since The 1960s

INVESTOPEDIA.COMOct 22, 9:06 PM UTC
4

The AI-related technology sector continues its broad retreat, with Celestica (CAD) shares tumbling 11.5% today amid pre-earnings risk reduction, insider selling, and a bearish technical pattern . The NASDAQ fell 2.6% as investors dumped AI names, including Nvidia, AMD, Broadcom, and Marvell Technology .

Even strong earnings reports are not immune: Western Digital (WDC) initially surged 4% after beating Q1 estimates and providing upbeat guidance, but subsequently erased all gains as the AI selloff extended . This indicates a strong bearish sentiment overriding positive company-specific news.

Key points:

  • Celestica (CAD): Down 11.5% on AI tech selloff, pre-earnings caution, insider sales.
  • Western Digital (WDC): Q1 beat and strong guidance negated by sector-wide selling.
  • Broader Impact: NASDAQ down 2.6%, with major AI players retreating .
Why is Celestica stock tumbling today?

Why is Celestica stock tumbling today?

INVESTING.COMOct 22, 7:07 PM UTC
Western Digital beats earnings estimates, but AI selloff erases initial gains

Western Digital beats earnings estimates, but AI selloff erases initial gains

STREETINSIDER.COMOct 22, 8:13 PM UTC
1 / 2
6

Freedom Broker has issued a sweeping downgrade across major North American gold producers, citing trimmed EBITDA forecasts, operational risks, and valuation constraints. This led to significant share price drops:

  • Agnico Eagle (AEM): Downgraded to Hold, PT cut to $212 (from $255) on valuation premium and revised 2027 EBITDA.
  • Barrick Mining (B): Downgraded to Hold, PT cut to $46 (from $54) due to near-term earnings estimate reductions.
  • Newmont (NEM): Downgraded to Hold, PT cut to $116 (from $130) on cost inflation and performance risks.

RBC Capital Markets also noted gold producers face margin pressure in Q3 from lower gold prices and elevated costs, despite expected production improvements .

Agnico, Barrick, and Newmont fall following broad Freedom Broker downgrades

Agnico, Barrick, and Newmont fall following broad Freedom Broker downgrades

STREETINSIDER.COMOct 22, 2:56 PM UTC
Gold miners face margin pressure as lower prices complicate third-quarter results

Gold miners face margin pressure as lower prices complicate third-quarter results

STREETINSIDER.COMOct 22, 7:58 PM UTC
1 / 2
6

US stock futures and major indices are sharply lower, led by a broad sell-off in the tech sector. Concerns over the long-term sustainability of AI infrastructure spending and rising borrowing costs are weighing on sentiment . Chip stocks, including Marvell Technology (-5%), Micron, Sandisk, Seagate, and Western Digital, are under pressure . Mega-cap tech names like Meta Platforms (-7%) and Tesla (-5.2%) are also declining despite mixed earnings reactions .

Key points:

  • AI Spending Doubts: Warnings from chip executives about capital access becoming a constraint on AI expansion and clouding ROI .
  • Broad Tech Weakness: Nasdaq Composite down 2.2%, S&P 500 down 1.2% .
  • Geopolitical Headwinds: Oil prices surge on Middle East escalations, contributing to a broad risk-off tone .
  • Memory Glut Fears: Nvidia CEO Jensen Huang attempts to counter concerns about a 2029 memory glut, but memory stocks remain under pressure .
Why is Marvell Technology stock sliding today?

Why is Marvell Technology stock sliding today?

INVESTING.COMOct 22, 1:46 PM UTC
Stock Market Today: Nasdaq, S&P 500 Dive, Led Lower by Tech Stocks; Oil Prices Surge on Middle East Escalations; 10-Year Yield Sinks Below 5%

Stock Market Today: Nasdaq, S&P 500 Dive, Led Lower by Tech Stocks; Oil Prices Surge on Middle East Escalations; 10-Year Yield Sinks Below 5%

INVESTOPEDIA.COMOct 22, 4:45 PM UTC
Sellers are back in tech, while bear market grips Chinese stocks

Sellers are back in tech, while bear market grips Chinese stocks

CNBC.COMOct 22, 11:50 AM UTC
JPMorgan says tech stocks lead U.S. futures lower on risks

JPMorgan says tech stocks lead U.S. futures lower on risks

STREETINSIDER.COMOct 22, 12:50 PM UTC
Nvidia’s Jensen Huang says he sees no sign of a 2029 memory glut: ‘You can always use more’

Nvidia’s Jensen Huang says he sees no sign of a 2029 memory glut: ‘You can always use more’

CNBC.COMOct 22, 1:12 PM UTC
Tech Slump Hits Memory, Data Storage Stocks With Western Digital Earnings Due Later Today

Tech Slump Hits Memory, Data Storage Stocks With Western Digital Earnings Due Later Today

INVESTOPEDIA.COMOct 22, 3:00 PM UTC
1 / 6
6